According to @StockMKTNewz, Novo Nordisk ($NVO) is launching a limited-time offer to sell its weight-loss drug Wegovy at a starting price of $199 per month for new patients, specifically targeting those switching from compounded versions. This promotion, valid until June 30th, could disrupt the pharmaceutical market by drawing customers away from generic competitors, as reported by WSJ. For traders, this move may drive increased volatility in $NVO shares and influence sentiment in healthcare-related crypto tokens, as traditional pharma shifts impact tokenized healthcare assets and blockchain-based supply chain platforms. Source: @StockMKTNewz, WSJ.